Cellular immunomonitoring (T-cell responses to peptides contained in IMA910 and analysis of other immune cell populations that may influence T-cell responses such as Tregs), serum levels of antibodies and molecules with suspected influence on immune response will be assessed on several occasions during the study. In a subgroup of patients the following parameters may be assessed in tumour tissue (depending on the amount and quality of tissue): expression of target genes encoding the TUMAPs contained in IMA910 and of genes which might be influenced by IMA910, presentation of TUMAPs contained in IMA910, presence of tumour infiltrating lymphocytes and presence of molecules with suspected influence on immune response.